Researchers leading the SWOG S1712 clinical trial have found that adding ... deep enough to warrant discontinuing treatment. A new preclinical model using CRISPR, an advanced technology that ...
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...
Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced Shaperon’s entry ...
Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.
Presentation of in vitro studies of RM-0256, a novel anti-PD-L1 antibody conjugated to IR700, which comprises a dual mode of photoimmunotherapy: depletion of PD-L1 expressing tumor cells and depletion ...
A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the ...
Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of ...
Surrozen is pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration. The milestone achievement triggers a $10 million payment to Surrozen as part ...
The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.
"We are thrilled with the positive outcomes from our preclinical studies," Biolexis ... the biotech plans to conduct IND-enabling studies and begin human clinical trials early next year, chief ...
The neuraxial delivery of drugs has become a cornerstone in the management of pain, leveraging the pivotal roles of the dorsal root ganglion (DRG) and dorsal horn. These spinal structures are key in ...
Kineta will be trading under the symbol “KANT” on OTC PinkKineta will continue to pursue strategic alternatives as previously announcedTuHURA ...